First-in-human data for the trispecific antibody “suggest a paradigm shift” for the relapsed/refractory multiple myeloma ...

The first-in-class antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) demonstrated promising efficacy and high response ...